


PHARMACEUTICAL 2021

ZOGENIX INC. Rank 213 of 402





PHARMACEUTICAL 2021

ZOGENIX INC. Rank 213 of 402

The relative strengths and weaknesses of ZOGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ZOGENIX INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of ZOGENIX INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 44% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	522,174
Cost of Goods Sold	542
Intangible Assets	104,792
Liabilities, Current	82,715
Liabilities, Non-Current	165,146
Other Assets	15,440
Other Compr. Net Income	-450
Other Expenses	5,817
Other Liabilities	33,600
Other Net Income	20,909
Other Revenues	13,643
Property and Equipment	8,724
Research and Development	138,002
Selling, General and Administrative Expense	99,574

Output Variable	Value in 1000 USD
Assets	651,130
Liabilities	281,461
Expenses	243,935
Revenues	13,643
Stockholders Equity	369,669
Net Income	-209,383
Comprehensive Net Income	-209,608
Economic Capital Ratio	91%

